Oxybutynin has 11 known drug interactions based on U.S. FDA drug labeling data. Of these, 2 are contraindicated combinations that should be avoided entirely. Notable interactions include combinations with Rivastigmine, Rivastigmine Tartrate, Carbamazepine. Patients taking Oxybutynin should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 11
- Contraindicated
- 2
- Moderate
- 9
Contraindicated (2)
- Oxybutynin + Rivastigmine— Rivastigmine may interfere with anticholinergic activity. Concomitant use not recommended unless clinically necessary.
- Oxybutynin + Rivastigmine Tartrate— Rivastigmine may interfere with anticholinergic activity of oxybutynin. Concomitant use not recommended unless clinicall…
Moderate (9)
- Oxybutynin + Carbamazepine— CYP3A4 inhibitor that increases carbamazepine plasma levels. Close monitoring of carbamazepine levels and dosage adjustm…
- Oxybutynin + Clarithromycin— Macrolide antibiotic and CYP3A4 inhibitor may alter oxybutynin pharmacokinetic parameters (Cmax and AUC). Caution should…
- Oxybutynin + Desmopressin Acetate— Concomitant use may increase risk of water intoxication with hyponatremia; requires more frequent serum sodium monitorin…
- Oxybutynin + Desmopressin Acetate Oral Solution— May increase risk of water intoxication with hyponatremia. Monitor serum sodium more frequently.
- Oxybutynin + Erythromycin— Macrolide antibiotic and CYP3A4 inhibitor may alter oxybutynin pharmacokinetic parameters (Cmax and AUC). Caution should…
- Oxybutynin + Itraconazole— CYP3A4 inhibitor may alter oxybutynin pharmacokinetic parameters (Cmax and AUC). Caution should be used when co-administ…
- Oxybutynin + Ketoconazole— Strong CYP3A4 inhibitor increases systemic exposure of oxybutynin approximately 2-fold. Caution should be used when co-a…
- Oxybutynin + Metoclopramide— Anticholinergic agents may antagonize the effects of prokinetic agents like metoclopramide. Monitor for reduced prokinet…
- Oxybutynin + Miconazole— CYP3A4 inhibitor may alter oxybutynin pharmacokinetic parameters (Cmax and AUC). Caution should be used when co-administ…